Prescribing guide
Jakafi (ruxolitinib)And Jakafi XR dosing, dose changes by hemoglobin and platelets, CBC monitoring and prior authorization for polycythemia veraFor prescribers and their offices treating polycythemia vera: what the pharmacy needs before it ships, what the prior authorization wants documented, the titration and the monitoring the label requires.
Dispensing gate
No boxed warning and no contraindications; the label names no REMS. Baseline CBC, infection history (tuberculosis, herpes simplex, herpes zoster, hepatitis B), TB risk assessment, prior authorization and specialty pharmacy routing precede the first fill.
Example PA threshold
FEP Blue example: age 18 or older, PV with inadequate response to or intolerance of hydroxyurea, no serious infections, CBC and lipid monitoring attestations, dose not above 55mg a day; 6-month approvals.
Monitoring
CBC before treatment and every 2 to 4 weeks until doses are stabilized, then as clinically indicated; lipids about 8 to 12 weeks after initiation; periodic skin examinations.
Support line
IncyteCARES, 1-855-452-5234, Monday through Friday 8 AM to 8 PM ET; benefits verification, prior authorization follow-ups, appeal information, Savings Program for commercial coverage, Patient Assistance Program, temporary supply for coverage delays.
Give your patient their plan
A one-page handout for starting Jakafi, in plain language: what the first fill waits on, the first dates, who will call and the symptoms to report, with blank lines for the start date and your office's number. The link opens the patient's full first 90 days page, where their dates become calendar entries.
trialfriend.com/p/jakafiBefore the first fill: REMS, labs and enrollment
The steps that the pharmacy, the REMS or the drugmaker's program will wait on, in the order they usually need to happen. A first fill of a specialty drug most often stalls on one of these rather than on the plan.
| Step | What it requires | Source |
|---|---|---|
| Confirm the indication | Polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea. Safety and effectiveness in pediatric patients with PV are not established. | FDA label |
| Baseline CBC | Section 2.1: perform a CBC before treatment. Section 5.1 warns of thrombocytopenia, anemia and neutropenia. | FDA label |
| Infection history and TB risk | Ask about past tuberculosis, herpes simplex, herpes zoster and hepatitis B. Evaluate TB risk factors and test those at higher risk for latent infection; consult a TB specialist for active or latent TB before starting. Delay starting until active serious infections have resolved. | FDA label |
| Choose the form | Jakafi tablets 5, 10, 15, 20 and 25mg, twice daily; Jakafi XR extended-release tablets 11, 22, 33, 44 and 55mg, once daily, swallowed whole. XR is not used where the label says so: ESRD on dialysis, and a prior Jakafi dose of 5mg twice daily when a strong CYP3A4 inhibitor or fluconazole is added. | FDA label |
| Check renal and hepatic function | PV starting dose is 5mg twice daily (XR 11mg once daily) in moderate or severe renal impairment and in any hepatic impairment (Child-Pugh A, B or C). ESRD on dialysis: 10mg once after each dialysis session, no XR. Avoid in ESRD not requiring dialysis. | FDA label |
| Review the medication list | Fluconazole, strong CYP3A4 inhibitors and strong CYP3A4 inducers change exposure; see the interactions table. | FDA label |
| Enroll in IncyteCARES | The office can enroll the patient, or the patient can call 1-855-452-5234 or bring a completed form to the office. Incyte says coverage is usually reported within 3 business days of receiving insurance information. | IncyteCARES FAQ |
| Route the prescription | Filled by a specialty pharmacy and shipped to the patient's home or the office; Incyte says it cannot be shipped to a local pharmacy. The payer may require a particular specialty pharmacy. | IncyteCARES FAQ |
| Coverage delays | IncyteCARES may offer eligible patients a free short-term supply when a coverage or appeal decision is delayed beyond a few business days. It can run a benefit verification for both Jakafi XR and Jakafi at enrollment. | IncyteCARES FAQ |
Prior authorization criteria and what to document
One public policy as the example: Blue Cross Blue Shield Federal Employee Program (FEP Blue), effective October 1, 2026. Approval 6 months, then 6 months at each renewal. This is policy 5.21.018, last reviewed September 17, 2026, and it cites the July 2026 label, so it covers both Jakafi and Jakafi XR. Renewal asks for a reduction in palpable spleen length or spleen volume, or symptomatic improvement, along with continued blood count monitoring. Other plans set their own criteria, so yours may differ.
| Element | What the policy asks | In the chart | Source |
|---|---|---|---|
| Age | 18 years of age and older for PV | Date of birth on the request | FEP Blue policy |
| Diagnosis | Polycythemia vera | Diagnosis and ICD-10 code in the chart note | FEP Blue policy |
| Hydroxyurea history | Inadequate treatment response to or intolerance to hydroxyurea | Dates and doses of hydroxyurea, with the response or the intolerance documented | FEP Blue policy |
| Infection status | No serious infections | Note that no serious infection is present at the start | FEP Blue policy |
| CBC monitoring | Prescriber agrees to monitor CBC and platelet counts | Baseline CBC with date and the monitoring plan | FEP Blue policy |
| Lipid monitoring | Prescriber agrees to assess lipid levels 8 to 12 weeks from the start of therapy and treat as needed | Planned lipid panel date | FEP Blue policy |
| Dose | Prescriber will not exceed the FDA labeled dose of 55mg a day | Prescribed form, strength and frequency | FEP Blue policy |
| Renewal | Every 6 months: a reduction in palpable spleen length or spleen volume, or symptomatic improvement, plus continued CBC and platelet monitoring and the 55mg a day limit | Spleen measurement or symptom note, and recent CBC | FEP Blue policy |
Jakafi dosing and titration
| When | Label | Source |
|---|---|---|
| Day 1 | Jakafi 10mg orally twice daily, or Jakafi XR 22mg orally once daily, with or without food. Jakafi XR tablets are swallowed whole, not split, chewed or crushed. | FDA label |
| Increase for insufficient response | Jakafi in 5mg twice daily increments to a maximum of 25mg twice daily; Jakafi XR in 11mg once daily increments to a maximum of 55mg once daily. Not during the first 4 weeks and not more often than every 2 weeks. | FDA label |
| Conditions for an increase | All of: inadequate efficacy (continued need for phlebotomy, WBC or platelets above the upper limit of normal, or palpable spleen reduced by less than 25% from baseline), platelets 140 x 10⁹/L or higher, hemoglobin 12g/dL or higher, and ANC 1.5 x 10⁹/L or higher. | FDA label |
| Table 7: hemoglobin 10 to less than 12g/dL AND platelets 75 to less than 100 x 10⁹/L | Dose reductions should be considered, with the goal of avoiding dose interruptions for anemia and thrombocytopenia. | FDA label |
| Table 7: hemoglobin 8 to less than 10g/dL OR platelets 50 to less than 75 x 10⁹/L | Jakafi: reduce by 5mg twice daily; on 5mg twice daily, reduce to 5mg once daily. Jakafi XR: reduce by 11mg once daily; on 11mg once daily, interrupt dosing. | FDA label |
| Table 7: hemoglobin less than 8g/dL OR platelets less than 50 x 10⁹/L | Interrupt dosing. The label also interrupts for ANC less than 1 x 10⁹/L. | FDA label |
| Table 8: restart, hemoglobin 8 to less than 10g/dL OR platelets 50 to less than 75 x 10⁹/L OR ANC 1 to less than 1.5 x 10⁹/L | Maximum 5mg twice daily (XR 11mg once daily), or no more than 5mg twice daily (XR 11mg once daily) less than the dose that led to the interruption. Continue at least 2 weeks; if stable, may increase by 5mg twice daily (XR 11mg once daily). | FDA label |
| Table 8: restart, hemoglobin 10 to less than 12g/dL OR platelets 75 to less than 100 x 10⁹/L OR ANC 1.5 to less than 2 x 10⁹/L | Maximum 10mg twice daily (XR 22mg once daily), or no more than 5mg twice daily (XR 11mg once daily) less than the dose that led to the interruption. | FDA label |
| Table 8: restart, hemoglobin 12g/dL or higher OR platelets 100 x 10⁹/L or higher OR ANC 2 x 10⁹/L or higher | Maximum 15mg twice daily (XR 33mg once daily), or no more than 5mg twice daily (XR 11mg once daily) less than the dose that led to the interruption. Use the most severe category of the 3 parameters. | FDA label |
| Interrupted at the lowest dose | After an interruption at 5mg twice daily, restart at 5mg twice daily or 5mg once daily, not higher; after one at XR 11mg once daily, restart at 11mg once daily, not higher. Both require hemoglobin 10g/dL or higher, platelets 75 x 10⁹/L or higher and ANC 1.5 x 10⁹/L or higher. | FDA label |
| After restarting | Doses may be titrated, but the maximum total daily dose should not exceed 5mg twice daily (XR 11mg once daily) less than the dose that led to the interruption. Interruption after phlebotomy-associated anemia is the exception, with no such limit. | FDA label |
| Renal impairment (PV) | Moderate (CLcr 30 to 59mL/min) or severe (CLcr 15 to 29mL/min): Jakafi 5mg twice daily or XR 11mg once daily. ESRD on dialysis: Jakafi 10mg once after the dialysis session; do not use XR. Avoid in ESRD (CLcr less than 15mL/min) not requiring dialysis. | FDA label |
| Hepatic impairment (PV) | Mild, moderate or severe (Child-Pugh A, B or C), any platelet count: Jakafi 5mg twice daily or XR 11mg once daily. | FDA label |
| Missed dose | No additional dose; take the next usual prescribed dose. Overdose: no known antidote; supportive treatment; hemodialysis is not expected to enhance elimination. | FDA label |
| Discontinuation | For reasons other than potentially life-threatening toxicities, taper gradually, for example by 5mg twice daily each week (XR by 11mg once daily each week). | FDA label |
| Nasogastric tube (Jakafi tablets only) | 8 French or greater: suspend 1 tablet in about 40mL of water, stir about 10 minutes, give within 6 hours of dispersion, and rinse the tube with about 75mL of water. | FDA label |
| Supply and storage | Jakafi in bottles of 60 tablets; Jakafi XR in bottles of 30. Store at 20 to 25°C (68 to 77°F), in a tight container, protected from light. | FDA label |
Monitoring the Jakafi label requires
| When | What | What the label says to do with it | Source |
|---|---|---|---|
| Before treatment | CBC; history of tuberculosis, herpes simplex, herpes zoster and hepatitis B; TB risk factors | Test those at higher TB risk for latent infection; delay starting until active serious infections resolve | FDA label |
| Every 2 to 4 weeks until doses are stabilized, then as clinically indicated | CBC | Reduce, interrupt and restart per Tables 7 and 8. In RESPONSE through week 32, anemia 72% against 58% on best available therapy, thrombocytopenia 27% against 24%, neutropenia 3% against 10% (laboratory values, all grades) | FDA label |
| About 8 to 12 weeks after initiation | Lipid parameters | Monitor and treat per hyperlipidemia guidelines. In RESPONSE, hypercholesterolemia 35% against 8% and hypertriglyceridemia 15% against 13% | FDA label |
| Throughout | Signs and symptoms of infection, including active tuberculosis, herpes zoster and herpes simplex | Manage promptly. Herpes zoster 6% against 0% in RESPONSE. Consider interrupting for disseminated herpes simplex. If PML is suspected, stop and evaluate. Use active surveillance and prophylactic antibiotics according to clinical guidelines | FDA label |
| Chronic HBV infection | HBV-DNA increases, with or without ALT and AST elevations, have been reported | Treat and monitor per clinical guidelines | FDA label |
| Periodically | Skin examination | Basal cell, squamous cell and Merkel cell carcinoma have occurred | FDA label |
| On interruption, taper or discontinuation | Flare of myeloproliferative neoplasm signs and symptoms; in some MF patients fever, respiratory distress, hypotension, DIC or multi-organ failure | Evaluate for and treat intercurrent illness and consider restarting or increasing the dose; instruct patients not to interrupt or stop without consulting their healthcare provider | FDA label |
| Before starting and when continuing | MACE, thrombosis and secondary malignancy risk, seen with another JAK inhibitor in rheumatoid arthritis | Weigh benefits and risks, particularly in current or past smokers and patients with cardiovascular risk factors or a known malignancy; evaluate thrombosis symptoms promptly. The label says thromboembolic event rates in MF and PV trials were similar with Jakafi and control | FDA label |
| RESPONSE safety summary | Diarrhea 15% against 7%, dizziness 15% against 13%, dyspnea 13% against 4%, muscle spasms 12% against 5% | Discontinuation for adverse events in 4% on Jakafi; postmarketing reports include hypoglycemia (class effect) | FDA label |
Jakafi drug interactions and contraindications
| Label category | Agents and what the label says | Source |
|---|---|---|
| Fluconazole above 200mg daily | Avoid concomitant use. | FDA label |
| Fluconazole 200mg or less, or strong CYP3A4 inhibitors: PV starting dose | Jakafi 5mg twice daily, or Jakafi XR 11mg once daily. | FDA label |
| Same agents, stable dose of 10mg twice daily or more (XR 22mg once daily or more) | Reduce the dose by 50%, rounding up to the closest available tablet strength. | FDA label |
| Same agents, stable dose of Jakafi 5mg twice daily | Jakafi 5mg once daily; do not use Jakafi XR. | FDA label |
| Same agents, stable dose of Jakafi 5mg once daily or XR 11mg once daily | Avoid the strong CYP3A4 inhibitor or fluconazole, or interrupt Jakafi for the duration of its use. | FDA label |
| Pharmacokinetic basis | Fluconazole 100 to 400mg once daily raises steady state ruxolitinib AUC by about 100% to 300%; ketoconazole raised Cmax by 33% and AUC by 91%. | FDA label |
| Strong CYP3A4 inducers | May decrease exposure; rifampin lowered Cmax by 32% and AUC by 61%. Monitor frequently and adjust the dose based on safety and efficacy. | FDA label |
| Moderate CYP3A4 inhibitors | Erythromycin raised Cmax by 8% and AUC by 27%; section 7 gives no dose change for PV. | FDA label |
| Lactation | Discontinue breastfeeding during treatment and for 2 weeks after the final dose. | FDA label |
Why a first fill stalls, and the fix
- Prior authorization pending or deniedIncyteCARES says it finds out whether your plan needs a prior authorization and then notifies your doctor. If coverage is denied, it can help you and your doctor file an appeal. The example policy on this page shows what one plan asks for.
- The approval ran outFEP Blue approves Jakafi for 6 months at a time. Its renewal asks for a smaller spleen or better symptoms, and for the prescriber to keep checking blood counts.
- The prescription went to a local pharmacyIncyte says Jakafi cannot be shipped to a local pharmacy. IncyteCARES can identify a specialty pharmacy that works with your insurance, and your plan may require a particular one.
- Jakafi XR is not coveredIncyteCARES can check benefits for both Jakafi XR and Jakafi at enrollment. If the plan denies Jakafi XR, it contacts your healthcare professional to discuss whether Jakafi is covered. Your healthcare professional decides which form is right for you.
- A copay you cannot payWith commercial prescription coverage, the IncyteCARES Savings Program may lower the cost to as little as $0, subject to limits. An annual maximum applies, and a plan's copay accumulator or maximizer program may reduce the value.
- Medicare, Medicaid or TRICARE coverageThe Savings Program is not open to people insured under federal or state prescription drug programs, including Medicare, Medicaid and TRICARE. Incyte says people with Medicare Part D or Medicaid may qualify for free medicine through its Patient Assistance Program. To qualify, they must meet household income requirements and other criteria.
- No insurance, or coverage exhausted or deniedThe IncyteCARES Patient Assistance Program may provide Jakafi free of charge to people who meet its household income criteria. Incyte says it gives conditional approval within 3 business days of a completed form, for up to 90 days. Proof of household income is due during that time, and you reapply every year.
- The insurer's decision is taking too longIncyte says a delay of more than a few business days is unusual. When it happens, IncyteCARES may offer eligible patients a free short-term supply through its Temporary Patient Assistance Program.
IncyteCARES for Jakafi or Jakafi XR
- A review of your insurance coverage and out-of-pocket costs for Jakafi or Jakafi XR
- The IncyteCARES Savings Program for commercial prescription coverage, as little as $0 subject to an annual maximum, not valid with Medicare Part D, Medicare Advantage, Medicaid, TRICARE or state assistance programs, or for uninsured or cash-paying patients
- The Patient Assistance Program, Jakafi free of charge for eligible uninsured or underinsured people who meet household income criteria, with a new application every year IncyteCARES FAQ
- A free short-term supply for eligible patients when an insurance decision is delayed by more than a few business days IncyteCARES FAQ
- Help with prior authorization requirements and with appeals if coverage is denied IncyteCARES FAQ
- Delivery from a specialty pharmacy to your home or your healthcare professional's office IncyteCARES FAQ
- Education about your treatment or condition, and connections to other support services
Questions prescribers' offices ask about Jakafi
What is the Jakafi starting dose for polycythemia vera?
10mg orally twice daily, or Jakafi XR 22mg orally once daily, per the label effective July 20, 2026. Increase in 5mg twice daily steps (XR 11mg once daily steps) to a maximum of 25mg twice daily (XR 55mg once daily), not during the first 4 weeks and not more often than every 2 weeks.
When is Jakafi reduced or interrupted in PV?
Interrupt for hemoglobin below 8g/dL, platelets below 50 x 10⁹/L or ANC below 1 x 10⁹/L, per the label effective July 20, 2026. For hemoglobin 8 to less than 10g/dL or platelets 50 to less than 75 x 10⁹/L, reduce by 5mg twice daily (XR by 11mg once daily); patients on 5mg twice daily go to 5mg once daily, and patients on XR 11mg interrupt.
What monitoring does the Jakafi label require?
A CBC before treatment and every 2 to 4 weeks until doses are stabilized, then as clinically indicated, per the label effective July 20, 2026. Lipid parameters are assessed about 8 to 12 weeks after initiation, periodic skin examinations are performed, and tuberculosis risk factors are evaluated before starting.
How is Jakafi dosed with fluconazole or strong CYP3A4 inhibitors in PV?
Start at 5mg twice daily, or Jakafi XR 11mg once daily, per the label effective July 20, 2026. On a stable dose of 10mg twice daily or more (XR 22mg or more), reduce by 50%, rounding up to the closest available tablet strength; avoid fluconazole doses above 200mg daily.
What do insurers ask for to approve Jakafi for PV?
FEP Blue policy 5.21.018, effective October 1, 2026, approves for 6 months at a time and cites the July 2026 label. It asks for age 18 or older, PV with an inadequate response or intolerance to hydroxyurea, no serious infections, agreement to monitor CBC and platelets and to assess lipids at 8 to 12 weeks, and a dose no higher than 55mg a day.
Free email alert
Get an email when the Jakafi label changes
One email the day the FDA revises the Jakafi prescribing information, with a summary of what changed. No trial alerts or newsletter, and you can stop anytime.
Label changes for Jakafi only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Sources
- JAKAFI (ruxolitinib) tablets and JAKAFI XR (ruxolitinib) extended-release tablets, prescribing information and Patient Information, label version 42, effective July 20, 2026, Incyte Corporation, via DailyMed and openFDA, 2026-07-20.
- NDA 217180 approval letter, Jakafi XR (ruxolitinib) extended-release tablets, FDA, 2026-05-01.
- Drugs@FDA application record, NDA 202192, JAKAFI (Incyte Corp), from the openFDA Drugs@FDA API, FDA, 2026-11-12.
- Patient Assistance | IncyteCARES for JAKAFI or JAKAFI XR, Incyte, 2026-11-12.
- Frequently Asked Questions | IncyteCARES for JAKAFI or JAKAFI XR, Incyte, 2026-11-12.
- Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea (The RESPONSE Trial), NCT01243944, ClinicalTrials.gov, 2026-11-12.
- 5.21.018 Jakafi (ruxolitinib), prior approval policy, effective October 1, 2026, Blue Cross Blue Shield Federal Employee Program, 2026-10-01.
A reference drawn from the July 20, 2026 label, the drugmaker's published program and one public insurer policy shown as an example, checked on November 12, 2026. Labels and policies change; the label on DailyMed and the plan's current policy govern. Trial Friend is not a medical provider. It reports what these documents say and does not judge whether a drug is safe or right for any patient; that is the prescriber's decision. Not a substitute for the prescribing information.